Medinotec Inc. Reports Q3 Revenue of $2.54M, Nine-Month Revenue Growth of 41.4%

Medinotec Inc. reported its financial results for the third quarter and nine months ended November 30, 2025, revealing a revenue of $2.54 million for the quarter, a slight decrease from $2.57 million in the same period last year. However, the company experienced a significant increase in revenue for the nine-month period, reporting $7.91 million compared to $5.59 million for the same period in 2024, marking a 41.4% year-over-year growth. The gross profit for the quarter was $1.35 million, up from $1.04 million in the prior year, while the nine-month gross profit also saw a substantial increase to $4.27 million from $2.47 million.

The company's net income for the third quarter was $403,411, compared to $310,311 in the same quarter of 2024, reflecting a 29.9% increase. For the nine-month period, net income rose to $863,761 from $682,264, indicating a 26.5% increase. The improved profitability can be attributed to a reduction in the cost of goods sold, which decreased from $1.52 million to $1.19 million for the quarter, and from $3.11 million to $3.63 million for the nine months, alongside increased operational efficiencies.

In terms of strategic developments, Medinotec has focused on expanding its market presence, particularly in the U.S. The company received FDA 510(k) approval for its flagship product, the Trachealator, in November 2021, which has facilitated its entry into the U.S. market. The company is actively pursuing opportunities to enhance its sales and distribution operations in the U.S. while continuing to strengthen its position in South Africa, where it generates the majority of its revenue. The company also established Medinotec Capital Proprietary Limited as a wholly owned subsidiary in South Africa, further solidifying its operational base.

Operationally, Medinotec reported a total asset value of $6.85 million as of November 30, 2025, a slight increase from $6.81 million at the end of February 2025. The company’s cash position improved to $2.86 million, up from $2.77 million, while accounts receivable decreased to $2.26 million from $2.61 million. The inventory also increased to $1.21 million from $988,341, reflecting the company's efforts to prepare for future sales. The company’s employee headcount remained stable, supporting its operational needs as it continues to expand.

Looking ahead, Medinotec's management expressed optimism regarding the company's financial performance and operational progress, indicating plans for potential uplisting to a national securities exchange, such as the Nasdaq Capital Market. However, management cautioned that there can be no assurance that the company will meet the necessary listing requirements or that any uplisting will occur. The company remains focused on diversifying its revenue streams and enhancing its market share in both South Africa and the United States.